Application of the system for detecting the expression of mir-30c-5p in predicting the curative effect of aspirin on patients with cardiovascular diseases

Abstract

The invention discloses an application of a system for detecting miR-30c-5p expression quantity in prediction of a curative effect of aspirin for treating cardiovascular disease patients. In the application disclosed by the invention, an ROC curve analysis is carried out on miR-30c-5p of platelet hyper-reactivity patients by taking non-platelet hyper-reactivity patients a control, the area under curve is 0.720, the sensitivity is 54.84%, and the specificity is 82.25%. The result shows that the expression quality of miR-30c-5p in venous blood of detected objects can be used for judging the clinical curative effect of aspirin for treating the cardiovascular disease patients.

Description

technical field

[0001] The invention relates to the application of a system for detecting the expression of miR-30c-5p in the field of biotechnology to predict the curative effect of aspirin on patients with cardiovascular diseases. Background technique

[0002] Aspirin (ASA) is a commonly used antiplatelet drug for secondary prevention of coronary heart disease patients. A large number of randomized double-blind clinical studies have confirmed that aspirin can significantly reduce the occurrence of adverse events such as malignant arrhythmia, non-fatal myocardial infarction, and sudden cardiac death. It is one of the standard treatment drugs recommended by the guidelines of the College of Cardiology (ACC) and the American Heart Association (AHA). Aspirin's inhibition of platelet aggregation has large individual differences and unpredictability in the population, which has been confirmed by many clinical studies. Although some patients take regular doses of aspirin for a lon...

Examples

Embodiment 1

[0029] Embodiment 1, be used for predicting the determination of aspirin to patients with cardiovascular and cerebrovascular diseases

[0030] 350 patients with high cardiovascular risk, the inclusion criteria are as follows: age ≥ 50 years; patients with at least one of the following cardiovascular disease risk factors: stable angina, acute coronary syndrome (ACS), percutaneous coronary intervention (PCI) surgery, coronary artery bypass graft (CABG) surgery and ischemic cerebrovascular. These 350 patients with high cardiovascular risk were obtained after excluding some patients according to the exclusion criteria. The exclusion criteria were one of the following conditions: platelet count less than 100×10 9 / L; blood system diseases; application of GP IIb / IIIa antagonists, warfarin or non-steroidal anti-inflammatory drugs; severe liver and kidney insufficiency; contraindications to aspirin use.

[0031] The clinical data of the selected patients were collected: demographic d...

Embodiment 2

[0043] Example 2. Screening of gene markers for predicting the clinical curative effect of aspirin on patients with cardiovascular and cerebrovascular diseases

[0044] Among the 40 patients who regularly took aspirin after coronary stenting, 20 typical patients who still had cardiovascular events after regular use of 100 mg / d aspirin antiplatelet therapy after coronary stenting were selected, named as the cardiovascular event group; The matched 20 patients who regularly used 100 mg / d aspirin antiplatelet therapy after coronary stenting without cardiovascular events were selected as the control group. There were no significant statistical differences in age, sex, body mass index, smoking, hypertension, hyperlipidemia, and previous myocardial infarction between the cardiovascular event group and the control group (P>0.05); There was no statistical difference in drug treatment and other aspects (P>0.05).

[0045] Quantitative PCR analyzer 7500 system was used to quantitatively ...

Embodiment 3

[0081] Example 3. Verification of microRNA markers used to predict the clinical efficacy of aspirin on patients with cardiovascular and cerebrovascular diseases

[0082] According to the detection method of platelet aggregation rate in Example 1, 310 cases of selected patients for the verification study of fluorescent quantitative PCR after microRNA screening were divided into groups, including 74 patients in the HAPR group and 236 patients in the No-HAPR group.

[0083] Whole blood microRNA was extracted from 310 patients selected for the validation study of fluorescent quantitative PCR after microRNA screening, and the extracted whole blood microRNA was reverse-transcribed and stored at -20°C; The 10 microRNAs in 2 were amplified, and the relative expression levels of these 10 microRNAs relative to U6 in the HAPR group and the No-HAPR group were quantitatively analyzed (Table 5). Correlation of clinical efficacy.

[0084] Table 5. Relative expression of 10 microRNAs in HRP ...

technical field

[0001] The invention relates to the application of a system for detecting the expression of miR-30c-5p in the field of biotechnology to predict the curative effect of aspirin on patients with cardiovascular diseases. Background technique

[0002] Aspirin (ASA) is a commonly used antiplatelet drug for secondary prevention of coronary heart disease patients. A large number of randomized double-blind clinical studies have confirmed that aspirin can significantly reduce the occurrence of adverse events such as malignant arrhythmia, non-fatal myocardial infarction, and sudden cardiac death. It is one of the standard treatment drugs recommended by the guidelines of the College of Cardiology (ACC) and the American Heart Association (AHA). Aspirin's inhibition of platelet aggregation has large individual differences and unpredictability in the population, which has been confirmed by many clinical studies. Although some patients take regular doses of aspirin for a lon...

Examples

Embodiment 1

[0029] Embodiment 1, be used for predicting the determination of aspirin to patients with cardiovascular and cerebrovascular diseases

[0030] 350 patients with high cardiovascular risk, the inclusion criteria are as follows: age ≥ 50 years; patients with at least one of the following cardiovascular disease risk factors: stable angina, acute coronary syndrome (ACS), percutaneous coronary intervention (PCI) surgery, coronary artery bypass graft (CABG) surgery and ischemic cerebrovascular. These 350 patients with high cardiovascular risk were obtained after excluding some patients according to the exclusion criteria. The exclusion criteria were one of the following conditions: platelet count less than 100×10 9 / L; blood system diseases; application of GP IIb / IIIa antagonists, warfarin or non-steroidal anti-inflammatory drugs; severe liver and kidney insufficiency; contraindications to aspirin use.

[0031] The clinical data of the selected patients were collected: demographic d...

Embodiment 2

[0043] Example 2. Screening of gene markers for predicting the clinical curative effect of aspirin on patients with cardiovascular and cerebrovascular diseases

[0044] Among the 40 patients who regularly took aspirin after coronary stenting, 20 typical patients who still had cardiovascular events after regular use of 100 mg / d aspirin antiplatelet therapy after coronary stenting were selected, named as the cardiovascular event group; The matched 20 patients who regularly used 100 mg / d aspirin antiplatelet therapy after coronary stenting without cardiovascular events were selected as the control group. There were no significant statistical differences in age, sex, body mass index, smoking, hypertension, hyperlipidemia, and previous myocardial infarction between the cardiovascular event group and the control group (P>0.05); There was no statistical difference in drug treatment and other aspects (P>0.05).

[0045] Quantitative PCR analyzer 7500 system was used to quantitatively ...

Embodiment 3

[0081] Example 3. Verification of microRNA markers used to predict the clinical efficacy of aspirin on patients with cardiovascular and cerebrovascular diseases

[0082] According to the detection method of platelet aggregation rate in Example 1, 310 cases of selected patients for the verification study of fluorescent quantitative PCR after microRNA screening were divided into groups, including 74 patients in the HAPR group and 236 patients in the No-HAPR group.

[0083] Whole blood microRNA was extracted from 310 patients selected for the validation study of fluorescent quantitative PCR after microRNA screening, and the extracted whole blood microRNA was reverse-transcribed and stored at -20°C; The 10 microRNAs in 2 were amplified, and the relative expression levels of these 10 microRNAs relative to U6 in the HAPR group and the No-HAPR group were quantitatively analyzed (Table 5). Correlation of clinical efficacy.

[0084] Table 5. Relative expression of 10 microRNAs in HRP ...

Images